Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry (Phase 5, Protocol No. P07981 [Also Known as MK 8616-064])

Trial Profile

Effect of Sugammadex Compared With Usual Care for Reversal of Neuromuscular Blockade Induced by Rocuronium on Incidence of Residual Blockade at PACU Entry (Phase 5, Protocol No. P07981 [Also Known as MK 8616-064])

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Oct 2015

At a glance

  • Drugs Sugammadex (Primary) ; Glycopyrrolate; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top